Highlights of This Issue 4907

SPECIAL FEATURES

4909 The Tissue Is the Issue: Personalized Medicine for Non-Small Cell Lung Cancer
Fred R. Hirsch, Murry W. Wynes, David R. Gandara, and Paul A. Bunn, Jr.
See article p. 4938

Comparing Survival Curves Using an Easy to Interpret Statistic
Kenneth R. Hess

Targeting Eukaryotic Translation Initiation Factor 4E (eIF4E) in Cancer
Andrew C. Hsieh and Davide Ruggero

Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary
Shakun M. Malik, Ke Liu, Xu Qiang, Rajeshwari Sridhara, Shenghui Tang, W. David McGuinn, Jr., S. Leigh Verbois, Anshu Marathe, Gene M. Williams, Robert Justice, and Richard Pazdur

Key Role of Phosphoinositide 3-Kinase Class IB in Pancreatic Cancer
Charlotte E. Edling, Federico Selvaggi, Richard Buus, Tania Maffucci, Pierluigi Di Sebastian, Helmut Friess, Paolo Innocenti, Hemant M. Kocher, and Marco Falasca

EMIL4-ALK Fusion Gene Assessment Using Metastatic Lymph Node Samples Obtained by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration
Yuichi Sakairi, Takahiro Nakajima, Kazuhiro Yasufuku, Daisuke Ikebe, Hajime Kageyama, Manabu Soda, Kengo Takeuchi, Makiko Itami, Toshihiko Iizasa, Ichiro Yoshino, Hirofumi Mano, and Hideki Kimura
See commentary p. 4909

Statistics in Clinical Cancer Research

4912 Comparing Survival Curves Using an Easy to Interpret Statistic
Kenneth R. Hess

Molecular Pathways

4914 Targeting Eukaryotic Translation Initiation Factor 4E (eIF4E) in Cancer
Andrew C. Hsieh and Davide Ruggero

Report from the FDA

4921 Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary
Shakun M. Malik, Ke Liu, Xu Qiang, Rajeshwari Sridhara, Shenghui Tang, W. David McGuinn, Jr., S. Leigh Verbois, Anshu Marathe, Gene M. Williams, Julie Bullock, Christoffer Tornoe, Sue Ching Lin, Terrance Ocheltree, Milinda Vialpando, Alice Kacuba, Robert Justice, and Richard Pazdur

CANCER THERAPY: PRECLINICAL

4946 Pharmacokinetic/Pharmacodynamic Modeling Identifies SN30000 and SN29751 as Tirapazamine Analogues with Improved Tissue Penetration and Hypoxic Cell Killing in Tumors
Kevin O. Hicks, Bromwyn G. Siim, Jagdish K. Jaiswal, Frederik B. Pruijna, Annie M. Fraser, Rita Patel, Alison Hogg, H.D. Sarath Liyanage, Mary Jo Dorie, J. Martin Brown, William A. Denny, Michael P. Hay, and William R. Wilson

4958 Novel Models of Myxoid Liposarcoma Xenografts Mimicking the Biological and Pharmacologic Features of Human Tumors
Robertta Irapolli, Elena Tamborinini, Emanuela Virdis, Ezia Bello, Eva Tarantino, Sergio Marchini, Federica Grosso, Roberta Sanfilippo, Alessandro Gronchi, Juan Carlos Tercero, Gabriella Pelosi, Paolo Casali, Silvana Pilotti, and Maurizio D’Incalci

4968 Radiation-Guided Drug Delivery to Mouse Models of Lung Cancer
Ghazal Hariri, Heping Yan, Hailun Wang, Zhaozhong Han, and Dennis E. Hallahan

4978 A Proteasome Inhibitor, Bortezomib, Inhibits Breast Cancer Growth and Reduces Osteolysis by Downregulating Metastatic Genes
Marc D. Jones, Julie C. Liu, Thomas K. Barthel, Sadiq Hussain, Erik Lovria, Dengfeng Cheng, Jesse A. Schoonmaker, Sudhanshu Mulay, David C. Ayers, Mary L. Bouxein, Gary S. Stein, Siddhartha Mukherjee, and Jane B. Lian
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5048</td>
<td>Gene Expression Analysis Identifies Potential Biomarkers of Neurofibromatosis Type 1 Including Adrenomedullin</td>
<td>Trent R. Hummel, Walter J. Jessen, Shyra C. Miller, Lan Kluwe, Victor F. Mautner, Margaret R. Wallace, Grier P. Page, Paul F. Worley, Bruce J. Aronow, Elizabeth K. Schorry, and Nancy Ratner</td>
</tr>
<tr>
<td>5058</td>
<td>Phase I Study of NK012, a Novel SN-38–Incorporating Micellar Nanoparticle, in Adult Patients with Solid Tumors</td>
<td>Tetsuya Hamaguchi, Toshihiko Doi, Takako Eguchi-Nakajima, Ken Kato, Yasuhide Yamada, Yasuhiro Shimada, Nozomu Fuse, Atsushi Ohtsu, Shin-ichi Matsumoto, Masaya Takanashi, and Yasuhiro Matsumura</td>
</tr>
<tr>
<td>5079</td>
<td>No Evidence of Sex-Related Survival Disparities among Head and Neck Cancer Patients Receiving Similar Multidisciplinary Care: A Matched-Pair Analysis</td>
<td>Jess C. Roberts, Guojun Li, Lorraine R. Reitzel, Qingyi Wei, and Erich M. Sturgis</td>
</tr>
<tr>
<td>5028</td>
<td>Pancreatic Cancer Screening in a Prospective Cohort of High-Risk Patients: A Comprehensive Strategy of Imaging and Genetics</td>
<td>Elizabeth C. Verna, Caroline Hwang, Peter D. Stevens, Heidrun Rotterdam, Stavros N. Stavropoulos, Carolyn D. Sy, Martin A. Prince, Wendy K. Chung, Robert L. Fine, John A. Chabot, and Harold Frucht</td>
</tr>
<tr>
<td>5038</td>
<td>Prognostic Gene Expression Signature for Squamous Cell Carcinoma of Lung</td>
<td>Chang-Qi Zhu, Dan Strumpf, Chun-Yan Li, Qing Li, Ni Liu, Sandy Der, Frances A. Shepherd, Ming-Sound Tsao, and Igor Jurisica</td>
</tr>
<tr>
<td>5019</td>
<td>No Evidence of Sex-Related Survival Disparities among Head and Neck Cancer Patients Receiving Similar Multidisciplinary Care: A Matched-Pair Analysis</td>
<td>Jess C. Roberts, Guojun Li, Lorraine R. Reitzel, Qingyi Wei, and Erich M. Sturgis</td>
</tr>
<tr>
<td>5002</td>
<td>Targeting the α Receptor for Platelet-Derived Growth Factor as a Primary or Combination Therapy in a Preclinical Model of Prostate Cancer Skeletal Metastasis</td>
<td>Mike R. Russell, Qingxin Liu, and Alessandro Fatatis</td>
</tr>
<tr>
<td>5087</td>
<td>Correction: Effect of Low-Dose Tamoxifen on Steroid Receptor Coactivator 3/Amplicated in Breast Cancer 1 in Normal and Malignant Human Breast Tissue</td>
<td>Chang-Qi Zhu, Dan Strumpf, Chun-Yan Li, Qing Li, Ni Liu, Sandy Der, Frances A. Shepherd, Ming-Sound Tsao, and Igor Jurisica</td>
</tr>
</tbody>
</table>
ABOUT THE COVER

A humanized, monoclonal antibody against PDGFRα was able to inhibit both early colonization of the bone and late progression of skeletal lesions in a murine model of prostate cancer metastasis. The image shows a metastatic tumor produced in the proximal femur by green fluorescent PC3-ML cells, four weeks after being inoculated via the hematogenous route. For further details, please see the article by Russell and colleagues on page 5002 of this issue.